CO2018000375A2 - Métodos para el tratamiento de trastornos de desarrollo con gaboxadol - Google Patents
Métodos para el tratamiento de trastornos de desarrollo con gaboxadolInfo
- Publication number
- CO2018000375A2 CO2018000375A2 CONC2018/0000375A CO2018000375A CO2018000375A2 CO 2018000375 A2 CO2018000375 A2 CO 2018000375A2 CO 2018000375 A CO2018000375 A CO 2018000375A CO 2018000375 A2 CO2018000375 A2 CO 2018000375A2
- Authority
- CO
- Colombia
- Prior art keywords
- gaboxadol
- patient
- acceptable salt
- syndrome
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 12
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 9
- 229950004346 gaboxadol Drugs 0.000 title abstract 9
- 208000012239 Developmental disease Diseases 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 238000001727 in vivo Methods 0.000 abstract 3
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Methods of treating a developmental disorder described herein include administering toa patient in need thereof about 0.05 mg to about 30 mg 15 gaboxadol ora pharmaceutically acceptable salt thereofwherein the method provides improvement in next day functioning. Methods of treating a developmental disorder described herein include administering toa patient in need thereof about 0.05 mg to about 30 mg gaboxadol ora pharmaceutically acceptable salt thereofwherein the method provides improvement in the 20 patient for more than 6 hours after administration to the patient. Methods of treating a developmental disorder are described herein which include administering toa patient in need thereof gaboxadol ora pharmaceutically acceptable salt thereofwherein the method provides an in vivo plasma profile including a Cmax less than about 400 ng/ml and wherein the method provides 25 improvement in the patient for more than 6 hours after administration of the gaboxadol ora pharmaceutically acceptable salt thereof. Methods oftreating a developmental disorder are described herein which include administering toa patient in need thereof gaboxadol ora pharmaceutically acceptable salt thereof wherein the method provides an in vivo plasma profile comprising a AUC 6•12 30 ofless than about 900 ng•hríml and wherein the method provides improvement in the patient for more than 6 hours after administration of the gaboxadol ora pharmaceutically acceptable salt thereof. Methods oftreating a developmental disorder are described herein which include administering toa patient in need thereof a first pharmaceutical composition comprising gaboxadol ora pharmaceutically acceptable salt thereof anda second pharmaceutical composition comprising gaboxadol ora pharmaceutically 5 acceptable salt thereofwherein the second pharmaceutical composition provides an in vivo plasma profile comprising a mean AUCo-oo of at least 20% less than the first pharmaceutical composition. In embodiments, the developmental disorder may be an Autistic Spectrum Disorder, pervasive developmental disorder, Autism, Angelman 1O syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Rett syndrome, Asperger's syndrome, Childhood Disintegrative Disorder, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562193717P | 2015-07-17 | 2015-07-17 | |
US201562207595P | 2015-08-20 | 2015-08-20 | |
US201662332567P | 2016-05-06 | 2016-05-06 | |
US201662346763P | 2016-06-07 | 2016-06-07 | |
US15/209,862 US20170014393A1 (en) | 2015-07-17 | 2016-07-14 | Methods of treating developmental disorders with gaboxadol |
PCT/US2016/042238 WO2017015049A1 (en) | 2015-07-17 | 2016-07-14 | Methods of treating developmental disorders with gaboxadol |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018000375A2 true CO2018000375A2 (es) | 2018-04-19 |
Family
ID=57774846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0000375A CO2018000375A2 (es) | 2015-07-17 | 2018-01-22 | Métodos para el tratamiento de trastornos de desarrollo con gaboxadol |
Country Status (16)
Country | Link |
---|---|
US (8) | US20170014393A1 (es) |
EP (1) | EP3324961A4 (es) |
JP (3) | JP2018520189A (es) |
KR (1) | KR20180031721A (es) |
CN (2) | CN116531370A (es) |
AU (2) | AU2016295138B2 (es) |
BR (1) | BR112018000933A2 (es) |
CA (1) | CA2992734A1 (es) |
CL (1) | CL2018000142A1 (es) |
CO (1) | CO2018000375A2 (es) |
HK (1) | HK1250951A1 (es) |
IL (2) | IL256912B2 (es) |
MX (2) | MX2018000745A (es) |
PE (2) | PE20190338A1 (es) |
TW (2) | TWI819995B (es) |
WO (1) | WO2017015049A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3372229T (pt) | 2014-06-06 | 2021-06-17 | Ovid Therapeutics Inc | Métodos para aumentar a inibição tónica e tratar a síndrome de angelman |
PE20190338A1 (es) | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
AU2018309049A1 (en) | 2017-08-04 | 2020-02-27 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
CN112739353A (zh) * | 2018-06-14 | 2021-04-30 | 奥维德医疗公司 | Mir-92a或mir-145在治疗安格曼综合征中的用途 |
KR20210049855A (ko) * | 2018-08-22 | 2021-05-06 | 오비드 테라퓨틱스 인크. | 위장관 장애들 및 천식의 치료에서 가복사돌의 사용 |
US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
WO2020106976A1 (en) * | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Combination of gaboxadol and lithium for the treatment of psychiatric disorders |
US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
AU2020288999A1 (en) * | 2019-06-07 | 2022-02-03 | Paxmedica, Inc. | Compositions and methods for treating central nervous system disorders |
CN114173765A (zh) * | 2019-07-15 | 2022-03-11 | 奥维德医疗公司 | 用于治疗性治疗的包含加波沙朵的药物制剂 |
MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830083A (en) | 1953-04-29 | 1958-04-08 | Allied Chem & Dye Corp | Production of aryloxy aliphatic carboxylic acids |
US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
US4138484A (en) | 1976-08-16 | 1979-02-06 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
AU2002227052A1 (en) * | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
KR20070010136A (ko) * | 2004-04-02 | 2007-01-22 | 하. 룬트벡 아크티에 셀스카브 | 가복사돌을 이용한 손상된 호흡 기능의 치료 |
JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
JP2010510314A (ja) * | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス,エルエルシー | 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法 |
WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
EP2334299A1 (en) * | 2008-09-01 | 2011-06-22 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat |
CN102147667A (zh) | 2010-02-08 | 2011-08-10 | 深圳富泰宏精密工业有限公司 | 触控笔 |
WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
WO2012075286A2 (en) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
EP3108876A1 (en) | 2011-10-13 | 2016-12-28 | Jaleva Pharmaceuticals LLC | Methods and compositions for rapid transbuccal delivery of active agents |
JP2016501876A (ja) * | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
WO2014123909A1 (en) | 2013-02-05 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
PT3372229T (pt) | 2014-06-06 | 2021-06-17 | Ovid Therapeutics Inc | Métodos para aumentar a inibição tónica e tratar a síndrome de angelman |
JP6491679B2 (ja) | 2014-06-12 | 2019-03-27 | ファイザー・リミテッドPfizer Limited | Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
PE20190338A1 (es) | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
EP3334427A4 (en) | 2015-08-11 | 2019-02-06 | Ovid Therapeutics, Inc. | METHODS OF SEDATION AND PARENTERAL COMPOSITION FOR USE IN INTENSIVE CARE |
US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
-
2016
- 2016-07-14 PE PE2018000085A patent/PE20190338A1/es unknown
- 2016-07-14 CA CA2992734A patent/CA2992734A1/en active Pending
- 2016-07-14 US US15/209,862 patent/US20170014393A1/en not_active Abandoned
- 2016-07-14 MX MX2018000745A patent/MX2018000745A/es unknown
- 2016-07-14 IL IL256912A patent/IL256912B2/en unknown
- 2016-07-14 JP JP2018502084A patent/JP2018520189A/ja not_active Withdrawn
- 2016-07-14 WO PCT/US2016/042238 patent/WO2017015049A1/en active Application Filing
- 2016-07-14 CN CN202310549878.XA patent/CN116531370A/zh active Pending
- 2016-07-14 BR BR112018000933A patent/BR112018000933A2/pt not_active Application Discontinuation
- 2016-07-14 IL IL305342A patent/IL305342A/en unknown
- 2016-07-14 EP EP16828266.3A patent/EP3324961A4/en active Pending
- 2016-07-14 CN CN201680054308.1A patent/CN108024997A/zh active Pending
- 2016-07-14 PE PE2022002752A patent/PE20230735A1/es unknown
- 2016-07-14 AU AU2016295138A patent/AU2016295138B2/en active Active
- 2016-07-14 KR KR1020187004863A patent/KR20180031721A/ko not_active Application Discontinuation
- 2016-07-15 TW TW105122538A patent/TWI819995B/zh active
- 2016-07-15 TW TW112110413A patent/TW202325293A/zh unknown
-
2017
- 2017-12-13 US US15/840,521 patent/US20180098974A1/en not_active Abandoned
-
2018
- 2018-01-17 CL CL2018000142A patent/CL2018000142A1/es unknown
- 2018-01-17 MX MX2022004734A patent/MX2022004734A/es unknown
- 2018-01-22 CO CONC2018/0000375A patent/CO2018000375A2/es unknown
- 2018-08-02 US US16/053,343 patent/US20180338960A1/en not_active Abandoned
- 2018-08-15 HK HK18110494.0A patent/HK1250951A1/zh unknown
- 2018-12-17 US US16/221,794 patent/US11096929B2/en active Active
-
2019
- 2019-05-01 US US16/400,227 patent/US20190255027A1/en not_active Abandoned
- 2019-06-25 US US16/451,591 patent/US20190321342A1/en not_active Abandoned
-
2020
- 2020-06-25 US US16/911,540 patent/US20210030727A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087584A patent/JP2021130687A/ja active Pending
- 2021-10-12 AU AU2021250862A patent/AU2021250862B2/en active Active
-
2022
- 2022-11-04 US US17/981,148 patent/US20230071127A1/en active Pending
-
2023
- 2023-05-16 JP JP2023080696A patent/JP2023103375A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018000375A2 (es) | Métodos para el tratamiento de trastornos de desarrollo con gaboxadol | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
MX2023008716A (es) | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. | |
WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
MX2016009427A (es) | Formulaciones de pridopidina de liberacion modificada. | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
JP2018520189A5 (es) | ||
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
JP2012180381A5 (es) | ||
CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
UA111599C2 (uk) | Композиція каспофунгіну | |
AR043822A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr | |
MX2019001937A (es) | Métodos de tratamiento de trastornos del desarrollo con biguanidas. | |
MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
BR112017025395A2 (pt) | formulações farmacêuticas para liberação prolongada de sebacoil éster de dinalbufina | |
RU2016143875A (ru) | Способ лечения двигательных расстройств бефирадолом | |
UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
MX2015011588A (es) | Tratamiento de combinacion. | |
UA115250C2 (uk) | Фармацевтичні комбінації | |
GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
AR105378A1 (es) | Métodos de tratamiento de trastornos del desarrollo con gaboxadol | |
WO2015130963A3 (en) | Compositions and methods for administering insulin or insulin-like protein to the brain | |
MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. |